Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 12:03 pm Purchase | 13G | ASTRIA THERAPEUTICS INC ATXS | Vestal Point Capital LP | 4,000,000 7.100% | 4,000,000 (New Position) | View |
| 2024-11-14 12:03 pm Purchase | 13G | Passage BIO Inc. PASG | Vestal Point Capital LP | 6,100,000 9.900% | 6,100,000 (New Position) | View |
| 2024-11-14 12:02 pm Purchase | 13G | Solid Biosciences Inc. SLDB | Vestal Point Capital LP | 2,800,000 7.300% | 2,800,000 (New Position) | View |
| 2024-11-14 12:02 pm Purchase | 13G | KalVista Pharmaceuticals Inc. KALV | Vestal Point Capital LP | 4,000,000 9.300% | 4,000,000 (New Position) | View |
| 2024-11-14 12:02 pm Purchase | 13G | Black Diamond Therapeutics Inc. BDTX | Vestal Point Capital LP | 5,028,500 8.900% | 5,028,500 (New Position) | View |
| 2024-11-14 12:01 pm Purchase | 13G | uniQure N.V. QURE | Vestal Point Capital LP | 4,750,000 9.800% | 825,000 (+21.02%) | View |
| 2024-11-14 12:00 pm Sale | 13G | Lyra Therapeutics Inc. LYRA | Vestal Point Capital LP | 0 0.000% | -3,000,000 (Position Closed) | View |
| 2024-11-14 12:00 pm Sale | 13G | Applied Therapeutics Inc. APLT | Vestal Point Capital LP | 1,145,000 1.000% | -3,010,000 (-72.44%) | View |
| 2024-02-13 4:34 pm Purchase | 13G | Applied Therapeutics Inc. APLT | Vestal Point Capital LP | 4,155,000 5.400% | 4,155,000 (New Position) | View |
| 2024-02-13 4:34 pm Purchase | 13G | Lyra Therapeutics Inc. LYRA | Vestal Point Capital LP | 3,000,000 5.700% | 3,000,000 (New Position) | View |
| 2024-02-13 4:33 pm Purchase | 13G | uniQure N.V. QURE | Vestal Point Capital LP | 3,925,000 8.200% | 3,925,000 (New Position) | View |